ARCA biopharma (FRA:HQ10) FCF Margin % : 0.00% (As of Jun. 2024)

View and export this data going back to 1997. Start your Free Trial

What is ARCA biopharma FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. ARCA biopharma's Free Cash Flow for the three months ended in Jun. 2024 was €-2.45 Mil. ARCA biopharma's Revenue for the three months ended in Jun. 2024 was €0.00 Mil. Therefore, ARCA biopharma's FCF Margin % for the quarter that ended in Jun. 2024 was 0.00%.

As of today, ARCA biopharma's current FCF Yield % is 0.00%.

The historical rank and industry rank for ARCA biopharma's FCF Margin % or its related term are showing as below:

FRA:HQ10's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -102.29
* Ranked among companies with meaningful FCF Margin % only.

ARCA biopharma FCF Margin % Historical Data

The historical data trend for ARCA biopharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARCA biopharma FCF Margin % Chart

ARCA biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

ARCA biopharma Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of ARCA biopharma's FCF Margin %

For the Biotechnology subindustry, ARCA biopharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ARCA biopharma's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ARCA biopharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where ARCA biopharma's FCF Margin % falls into.

Save Embed

;

Save Embed

;

ARCA biopharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

ARCA biopharma's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-4.598	/	0
	=	%

ARCA biopharma's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	-2.447	/	0
	=	%

ARCA biopharma FCF Margin % Related Terms

Thank you for viewing the detailed overview of ARCA biopharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

ARCA biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARCA biopharma Inc (FRA:HQ10) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

10170 Church Ranch Way, Suite 100, Westminster, CO, USA, 80021

Website

https://www.arcabio.com

ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.

ARCA biopharma Headlines

No Headlines